Advances in immunotherapy for triple-negative breast cancer

[1]  M. Pan,et al.  Combination of FAK inhibitor and cytokine-induced killer cell therapy: An alternative therapeutic strategy for patients with triple-negative breast cancer. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[2]  B. Lawal,et al.  Identification of INFG/STAT1/NOTCH3 as γ-Mangostin's potential targets for overcoming doxorubicin resistance and reducing cancer-associated fibroblasts in triple-negative breast cancer. , 2023, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[3]  R. Chakrabarti,et al.  Immature natural killer cells promote progression of triple-negative breast cancer , 2023, Science Translational Medicine.

[4]  B. Giri,et al.  Cancer-associated fibroblasts: The chief architect in the tumor microenvironment , 2023, Frontiers in Cell and Developmental Biology.

[5]  C. June,et al.  Chimeric antigen receptor T cells as adjuvant therapy for unresectable adenocarcinoma , 2023, Science advances.

[6]  S. Rieder,et al.  In or out of control: Modulating regulatory T cell homeostasis and function with immune checkpoint pathways , 2022, Frontiers in Immunology.

[7]  Mengke Niu,et al.  Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer , 2022, Journal for ImmunoTherapy of Cancer.

[8]  M. Galsky,et al.  Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors , 2022, JAMA oncology.

[9]  W. Zwart,et al.  MYC promotes immune-suppression in triple-negative breast cancer via inhibition of interferon signaling , 2022, Nature Communications.

[10]  Sung-Bae Kim,et al.  GLORIA: phase III, open-label study of adagloxad simolenin/OBI-821 in patients with high-risk triple-negative breast cancer. , 2022, Future oncology.

[11]  Hubing Shi,et al.  Improvement of TNBC immune checkpoint blockade with a microwave-controlled ozone release nanosystem. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[12]  Shuya Zhang,et al.  Targeting therapy and tumor microenvironment remodeling of triple-negative breast cancer by ginsenoside Rg3 based liposomes , 2022, Journal of Nanobiotechnology.

[13]  Hongyan Zhu,et al.  A tumor cell membrane-coated self-amplified nanosystem as a nanovaccine to boost the therapeutic effect of anti-PD-L1 antibody , 2022, Bioactive materials.

[14]  Y. Duan,et al.  Systemic Delivery of mPEG‐Masked Trispecific T‐Cell Nanoengagers in Synergy with STING Agonists Overcomes Immunotherapy Resistance in TNBC and Generates a Vaccination Effect , 2022, Advanced science.

[15]  Marianne M. Lee,et al.  Restoration of p53 activity via intracellular protein delivery sensitizes triple negative breast cancer to anti-PD-1 immunotherapy , 2022, Journal for ImmunoTherapy of Cancer.

[16]  Jindong Li,et al.  Hypoxia induces docetaxel resistance in triple-negative breast cancer via the HIF-1α/miR-494/Survivin signaling pathway , 2022, Neoplasia.

[17]  Jinchao Zhang,et al.  Biomineralized hydrogel DC vaccine for cancer immunotherapy: A boosting strategy via improving immunogenicity and reversing immune-inhibitory microenvironment. , 2022, Biomaterials.

[18]  E. B. Butler,et al.  A Phase 2 Trial of Enhancing Immune Checkpoint Blockade by Stereotactic Radiation and In Situ Virus Gene Therapy in Metastatic Triple-Negative Breast Cancer , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[19]  A. Vincent-Salomon,et al.  Lipid-associated macrophages are induced by cancer-associated fibroblasts and mediate immune suppression in breast cancer. , 2022, Cancer research.

[20]  S. Loi,et al.  Pembrolizumab plus Chemotherapy in Advanced Triple-Negative Breast Cancer. , 2022, The New England journal of medicine.

[21]  S. Chupradit,et al.  Potential of chimeric antigen receptor (CAR)‐redirected immune cells in breast cancer therapies: Recent advances , 2022, Journal of cellular and molecular medicine.

[22]  Kathleen E. Houlahan,et al.  Combinatorial immunotherapies overcome MYC-driven immune evasion in triple negative breast cancer , 2022, Nature Communications.

[23]  Xichun Hu,et al.  Mammary adipocytes protect triple-negative breast cancer cells from ferroptosis , 2022, Journal of Hematology & Oncology.

[24]  Chiun-Sheng Huang,et al.  The clinical relevance of humoral immune responses to Globo H-KLH vaccine adagloxad simolenin (OBI-822)/OBI-821 and expression of Globo H in metastatic breast cancer , 2022, Journal for ImmunoTherapy of Cancer.

[25]  Hebao Yuan,et al.  Albumin nanoparticle containing a PI3Kγ inhibitor and paclitaxel in combination with α-PD1 induces tumor remission of breast cancer in mice , 2022, Science Translational Medicine.

[26]  Hongzhong Li,et al.  Gut microbiota influence immunotherapy responses: mechanisms and therapeutic strategies , 2022, Journal of Hematology & Oncology.

[27]  Jiasheng Tu,et al.  A bio-responsive, cargo-catchable gel for postsurgical tumor treatment via ICD-based immunotherapy. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[28]  A. Ghallab,et al.  CXCR2 Small-Molecule Antagonist Combats Chemoresistance and Enhances Immunotherapy in Triple-Negative Breast Cancer , 2022, Frontiers in Pharmacology.

[29]  N. Che,et al.  Landscape of the Peripheral Immune Response Induced by Local Microwave Ablation in Patients with Breast Cancer , 2022, Advanced science.

[30]  Jianping Zhou,et al.  The programmed site-specific delivery of LY3200882 and PD-L1 siRNA boosts immunotherapy for triple-negative breast cancer by remodeling tumor microenvironment. , 2022, Biomaterials.

[31]  S. Demaria,et al.  Radiation therapy-induced remodeling of the tumor immune microenvironment. , 2022, Seminars in cancer biology.

[32]  Xin Hu,et al.  Combined angiogenesis and PD-1 inhibition for immunomodulatory TNBC: concept exploration and biomarker analysis in the FUTURE-C-Plus trial , 2022, Molecular cancer.

[33]  H. Rugo,et al.  Immunotherapy for early triple negative breast cancer: research agenda for the next decade , 2022, NPJ breast cancer.

[34]  E. Winer,et al.  Phase 1b Clinical Trial with Alpelisib plus Olaparib for Patients with Advanced Triple-Negative Breast Cancer. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  Yisheng Fan,et al.  The Characteristics of Tumor Microenvironment in Triple Negative Breast Cancer , 2022, Cancer management and research.

[36]  Tianfeng Chen,et al.  Ruthenium complexes boost NK cell immunotherapy via sensitizing triple-negative breast cancer and shaping immuno-microenvironment. , 2022, Biomaterials.

[37]  L. Gianni,et al.  Treatment landscape of triple-negative breast cancer — expanded options, evolving needs , 2021, Nature Reviews Clinical Oncology.

[38]  Zihua Zeng,et al.  Targeted immunotherapy of triple-negative breast cancer by aptamer-engineered NK cells. , 2021, Biomaterials.

[39]  Yanhu Li,et al.  Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer , 2021, Journal for ImmunoTherapy of Cancer.

[40]  H. Kim,et al.  Abscopal Effect of Radiotherapy Enhanced with Immune Checkpoint Inhibitors of Triple Negative Breast Cancer in 4T1 Mammary Carcinoma Model , 2021, International journal of molecular sciences.

[41]  Yunping Luo,et al.  Sharpening up tumor microenvironment to enhance the efficacy of immune checkpoint blockade on head and neck cancer using a CpG-oligodeoxynucleotide , 2021, Cancer Immunology, Immunotherapy.

[42]  E. Yang,et al.  Harnessing DNA Repair Defects to Augment Immune-Based Therapies in Triple-Negative Breast Cancer , 2021, Frontiers in Oncology.

[43]  Keda Yu,et al.  The advance of adjuvant treatment for triple-negative breast cancer , 2021, Cancer biology & medicine.

[44]  A. Schneeweiss,et al.  First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[45]  X. Guan,et al.  Progress and challenges of immunotherapy in triple-negative breast cancer. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[46]  Y. Wang,et al.  Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[47]  Jie Sun,et al.  Platinum-Based Chemotherapy and Immunotherapy in Early Triple-Negative Breast Cancer: A Meta-Analysis and Indirect Treatment Comparison , 2021, Frontiers in Oncology.

[48]  R. Gelber,et al.  Adjuvant Olaparib for Patients with BRCA1- or BRCA2-Mutated Breast Cancer. , 2021, The New England journal of medicine.

[49]  A. Tan,et al.  Checkpoint inhibitor therapy for metastatic triple-negative breast cancer , 2021, Cancer and Metastasis Reviews.

[50]  A. Gogia,et al.  Pembrolizumab monotherapy in advanced triple-negative breast cancer. , 2021, The Lancet. Oncology.

[51]  Yeon-Hee Park,et al.  BEGONIA: Phase 1b/2 study of durvalumab (D) combinations in locally advanced/metastatic triple-negative breast cancer (TNBC)—Initial results from arm 1, d+paclitaxel (P), and arm 6, d+trastuzumab deruxtecan (T-DXd). , 2021 .

[52]  P. Fasching,et al.  Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neodjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC). , 2021, Journal of Clinical Oncology.

[53]  R. Deng,et al.  FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer , 2021, Nature Communications.

[54]  A. Rody,et al.  Inhibitors of PD-1/PD-L1 and ERK1/2 impede the proliferation of receptor positive and triple-negative breast cancer cell lines , 2021, Journal of Cancer Research and Clinical Oncology.

[55]  V. Karantza,et al.  Eribulin Plus Pembrolizumab in Patients with Metastatic Triple-Negative Breast Cancer (ENHANCE 1): A Phase Ib/II Study , 2021, Clinical Cancer Research.

[56]  M. Chan,et al.  Efficient intracellular delivery of p53 protein by engineered protein crystals restores tumor suppressing function in vivo. , 2021, Biomaterials.

[57]  E. Winer,et al.  Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial. , 2021, The Lancet. Oncology.

[58]  Cheng-Bei Zhou,et al.  Gut Microbiota in Cancer Immune Response and Immunotherapy. , 2021, Trends in cancer.

[59]  Baolin Zhang,et al.  Cancer Immunotherapy Update: FDA-Approved Checkpoint Inhibitors and Companion Diagnostics , 2021, The AAPS Journal.

[60]  S. Loi,et al.  Abstract GS3-01: Additional efficacy endpoints from the phase 3 KEYNOTE-355 study of pembrolizumab plus chemotherapy vs placebo plus chemotherapy as first-line therapy for locally recurrent inoperable or metastatic triple-negative breast cancer , 2021 .

[61]  S. Loi,et al.  A phase II randomized trial of cobimetinib plus chemotherapy, with or without atezolizumab, as first-line treatment for patients with locally advanced or metastatic triple-negative breast cancer (COLET): primary analysis. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

[62]  Noah Dephoure,et al.  Radiotherapy-exposed CD8+ and CD4+ neoantigens enhance tumor control. , 2021, The Journal of clinical investigation.

[63]  I. Bièche,et al.  Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial , 2021, Nature Medicine.

[64]  A. Hanby,et al.  Inhibition of interferon-signalling halts cancer-associated fibroblast-dependent protection of breast cancer cells from chemotherapy , 2021, British journal of cancer.

[65]  M. Greabu,et al.  PI3K/AKT/mTOR Signaling Pathway in Breast Cancer: From Molecular Landscape to Clinical Aspects , 2020, International journal of molecular sciences.

[66]  Hongmei Zhou,et al.  Transforming Growth Factor-β Signaling in Fibrotic Diseases and Cancer-Associated Fibroblasts , 2020, Biomolecules.

[67]  Ahn， Jin Hee,et al.  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial , 2020, The Lancet.

[68]  L. Vega,et al.  Anacardic 6-pentadecyl salicylic acid induces apoptosis in breast cancer tumor cells, immunostimulation in the host and decreases blood toxic effects of taxol in an animal model. , 2020, Toxicology and applied pharmacology.

[69]  A. Memarian,et al.  Natural Killer Cell Defects in Breast Cancer: A Key Pathway for Tumor Evasion , 2020, International reviews of immunology.

[70]  J. Cui,et al.  Discrepant antitumor efficacies of three CpG oligodeoxynucleotide classes in monotherapy and co-therapy with PD-1 blockade. , 2020, Pharmacological research.

[71]  H. Iwata,et al.  Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial , 2020, The Lancet.

[72]  Yuhong Yang,et al.  Identification of CTLA-4 associated with tumor microenvironment and competing interactions in triple negative breast cancer by co-expression network analysis , 2020, Journal of Cancer.

[73]  I. Endo,et al.  CD8 T Cell Score as a Prognostic Biomarker for Triple Negative Breast Cancer , 2020, International journal of molecular sciences.

[74]  Kehao Le,et al.  M2 macrophage-induced lncRNA PCAT6 facilitates tumorigenesis and angiogenesis of triple-negative breast cancer through modulation of VEGFR2 , 2020, Cell Death & Disease.

[75]  Ye Du,et al.  A miR-210-3p regulon that controls the Warburg effect by modulating HIF-1α and p53 activity in triple-negative breast cancer , 2020, Cell Death & Disease.

[76]  Juanita Lopez,et al.  LBA41 LEAP-005: Phase II study of lenvatinib (len) plus pembrolizumab (pembro) in patients (pts) with previously treated advanced solid tumours , 2020 .

[77]  J. Rhee,et al.  Combined NK cell therapy and radiotherapy exhibit long-term therapeutic and anti-metastatic effects in a human triple negative breast cancer model. , 2020, International journal of radiation oncology, biology, physics.

[78]  Tianfeng Chen,et al.  Boosting Natural Killer Cell-Based Cancer Immunotherapy with Selenocystine/Transforming Growth Factor-Beta Inhibitor-Encapsulated Nanoemulsion. , 2020, ACS nano.

[79]  S. Gulati,et al.  Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. , 2020, The Lancet. Oncology.

[80]  Yang Luo,et al.  Dose-dense paclitaxel plus carboplatin vs. epirubicin and cyclophosphamide with paclitaxel as adjuvant chemotherapy for high-risk triple-negative breast cancer , 2020, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

[81]  W. Jacot,et al.  Prognostic Value of CXCR2 in Breast Cancer , 2020, Cancers.

[82]  L. Pusztai,et al.  PD-L1 Protein Expression on Both Tumor Cells and Macrophages are Associated with Response to Neoadjuvant Durvalumab with Chemotherapy in Triple-negative Breast Cancer , 2020, Clinical Cancer Research.

[83]  C. Sotiriou,et al.  Differential Benefit of Adjuvant Docetaxel-Based Chemotherapy in Patients With Early Breast Cancer According to Baseline Body Mass Index. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[84]  B. Cetin,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[85]  J. O’Shaughnessy,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. Reply. , 2020, The New England journal of medicine.

[86]  P. Savas,et al.  Phase 1b study evaluating a triplet combination of ipatasertib (IPAT), atezolizumab (Atezo), and paclitaxel (PAC) or nab-PAC as first-line (1L) therapy for locally advanced/metastatic triple-negative breast cancer (aTNBC) , 2020, Geburtshilfe und Frauenheilkunde.

[87]  Sung-Bae Kim,et al.  Preliminary safety and efficacy of GX-I7, a long-acting interleukin-7, in combination with pembrolizumab in patients with refractory or recurrent metastatic triple negative breast cancer (mTNBC): Dose escalation period of Phase Ib/II study (KEYNOTE-899). , 2020 .

[88]  V. Karantza,et al.  A phase Ib/II study of eribulin (ERI) plus pembrolizumab (PEMBRO) in metastatic triple-negative breast cancer (mTNBC) (ENHANCE 1). , 2020 .

[89]  D. Slamon,et al.  Results of ENCORE 602 (TRIO025), a phase II, randomized, placebo-controlled, double-blinded, multicenter study of atezolizumab with or without entinostat in patients with advanced triple-negative breast cancer (aTNBC). , 2020 .

[90]  M. Yamauchi,et al.  Fibroblast heterogeneity and its impact on extracellular matrix and immune landscape remodeling in cancer. , 2020, Matrix biology : journal of the International Society for Matrix Biology.

[91]  R. Kontermann,et al.  Inhibition of Tumor Cell Growth and Cancer Stem Cell Expansion by a Bispecific Antibody Targeting EGFR and HER3 , 2020, Molecular Cancer Therapeutics.

[92]  P. Buckhaults,et al.  Targeting lysyl oxidase (LOX) overcomes chemotherapy resistance in triple negative breast cancer , 2020, Nature Communications.

[93]  K. Mangold,et al.  LyP-1-modified oncolytic adenoviruses targeting transforming growth factor β inhibit tumor growth and metastases and augment immune checkpoint inhibitor therapy in breast cancer mouse models. , 2020, Human gene therapy.

[94]  H. Yao,et al.  Efficacy and safety of camrelizumab combined with apatinib in advanced triple-negative breast cancer: an open-label phase II trial , 2020, Journal for immunotherapy of cancer.

[95]  R. Bargou,et al.  T cell-engaging therapies — BiTEs and beyond , 2020, Nature Reviews Clinical Oncology.

[96]  M. Hellmann,et al.  Acquired Resistance to Immune Checkpoint Inhibitors. , 2020, Cancer cell.

[97]  P. Fasching,et al.  Pembrolizumab for Early Triple-Negative Breast Cancer. , 2020, The New England journal of medicine.

[98]  Chiun-Sheng Huang,et al.  Abstract GS3-04: Pathologic complete response (pCR) to neoadjuvant treatment with or without atezolizumab in triple negative, early high-risk and locally advanced breast cancer. NeoTRIPaPDL1 Michelangelo randomized study , 2020 .

[99]  Sung-Bae Kim,et al.  Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[100]  D. Berry,et al.  Effect of Pembrolizumab Plus Neoadjuvant Chemotherapy on Pathologic Complete Response in Women With Early-Stage Breast Cancer: An Analysis of the Ongoing Phase 2 Adaptively Randomized I-SPY2 Trial. , 2020, JAMA oncology.

[101]  B. Baradaran,et al.  CTLA-4: From mechanism to autoimmune therapy. , 2020, International immunopharmacology.

[102]  A. Rosato,et al.  Adoptive cell therapy of triple negative breast cancer with redirected cytokine-induced killer cells , 2020, Oncoimmunology.

[103]  M. Pan,et al.  Impact of FAK Expression on the Cytotoxic Effects of CIK Therapy in Triple-Negative Breast Cancer , 2019, Cancers.

[104]  Betty Y. S. Kim,et al.  Low-Dose Anti-Angiogenic Therapy Sensitizes Breast Cancer to PD-1 Blockade , 2019, Clinical Cancer Research.

[105]  E. Winer,et al.  Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.

[106]  H. McArthur,et al.  A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple‐negative breast cancer , 2019, Cancer.

[107]  L. Quintanilla‐Martinez,et al.  GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells , 2019, Oncoimmunology.

[108]  C. Sotiriou,et al.  Unraveling Triple-Negative Breast Cancer Tumor Microenvironment Heterogeneity: Towards an Optimized Treatment Approach , 2019, Journal of the National Cancer Institute.

[109]  C. Bokemeyer,et al.  Targeting the TIGIT-PVR immune checkpoint axis as novel therapeutic option in breast cancer , 2019, Oncoimmunology.

[110]  Zhi-gang Zhang,et al.  The Diverse Function of PD-1/PD-L Pathway Beyond Cancer , 2019, Front. Immunol..

[111]  Yuan Ji,et al.  An oncolytic adenovirus targeting TGFβ inhibits pro-tumorigenic signals and produces immune activation: A novel approach to enhance anti-PD-1 and anti-CTLA-4 therapy. , 2019, Human gene therapy.

[112]  Christopher B. Howard,et al.  Multifunctional lipid-coated calcium phosphate nanoplatforms for complete inhibition of large triple negative breast cancer via targeted combined therapy. , 2019, Biomaterials.

[113]  Tao Wang,et al.  JS001, an anti-PD-1 mAb for advanced triple negative breast cancer patients after multi-line systemic therapy in a phase I trial. , 2019, Annals of translational medicine.

[114]  Z. Zeng,et al.  Neoantigen vaccine: an emerging tumor immunotherapy , 2019, Molecular Cancer.

[115]  K. Weber,et al.  A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[116]  Nancy R. Zhang,et al.  Opposing Functions of Interferon Coordinate Adaptive and Innate Immune Responses to Cancer Immune Checkpoint Blockade , 2019, Cell.

[117]  N. Hacohen,et al.  PD-1 blockade in subprimed CD8 cells induces dysfunctional PD-1+CD38hi cells and anti-PD-1 resistance , 2019, Nature Immunology.

[118]  L. Zitvogel,et al.  Clinical evidence that immunogenic cell death sensitizes to PD-1/PD-L1 blockade , 2019, Oncoimmunology.

[119]  X. Zhang,et al.  Immuno-subtyping of breast cancer reveals distinct myeloid cell profiles and immunotherapy resistance mechanisms , 2019, Nature Cell Biology.

[120]  R. Castellano,et al.  A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer , 2019, Front. Immunol..

[121]  Jeong-Seok Nam,et al.  Targeting Cancer Stem Cells in Triple-Negative Breast Cancer , 2019, Cancers.

[122]  A. Tan,et al.  Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. , 2019, JAMA oncology.

[123]  N. Mohan,et al.  Atezolizumab potentiates Tcell-mediated cytotoxicity and coordinates with FAK to suppress cell invasion and motility in PD-L1+ triple negative breast cancer cells , 2019, Oncoimmunology.

[124]  Mahboubeh Yazdanifar,et al.  CAR T Cells Targeting the Tumor MUC1 Glycoprotein Reduce Triple-Negative Breast Cancer Growth , 2019, Front. Immunol..

[125]  H. Horlings,et al.  Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial , 2019, Nature Medicine.

[126]  G. Shapiro,et al.  PARP Inhibitor Efficacy Depends on CD8+ T-cell Recruitment via Intratumoral STING Pathway Activation in BRCA-Deficient Models of Triple-Negative Breast Cancer. , 2019, Cancer discovery.

[127]  Xin Hu,et al.  Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies. , 2019, Cancer cell.

[128]  S. O'Reilly,et al.  Atezolizumab and Nab-Paclitaxel in Advanced Triple-Negative Breast Cancer. , 2019, The New England journal of medicine.

[129]  E. Winer,et al.  Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[130]  S. Loi,et al.  Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

[131]  S. Adams,et al.  Atezolizumab Plus nab-Paclitaxel in the Treatment of Metastatic Triple-Negative Breast Cancer With 2-Year Survival Follow-up: A Phase 1b Clinical Trial , 2019, JAMA oncology.

[132]  Yue Yu,et al.  EGFR/Notch Antagonists Enhance the Response to Inhibitors of the PI3K-Akt Pathway by Decreasing Tumor-Initiating Cell Frequency , 2019, Clinical Cancer Research.

[133]  H. Lenz,et al.  Reprogramming Exosomes as Nanoscale Controllers of Cellular Immunity. , 2018, Journal of the American Chemical Society.

[134]  Andrew N Lane,et al.  Collagen prolyl 4-hydroxylase 1 is essential for HIF-1α stabilization and TNBC chemoresistance , 2018, Nature Communications.

[135]  E. Levy,et al.  Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells , 2018, Front. Immunol..

[136]  K. Hargadon,et al.  Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. , 2018, International immunopharmacology.

[137]  Masafumi Nakamura,et al.  Catumaxomab with Activated T-cells Efficiently Lyses Chemoresistant EpCAM-positive Triple-negative Breast Cancer Cell Lines , 2018, AntiCancer Research.

[138]  M. Oliveira,et al.  Interferon-Gamma at the Crossroads of Tumor Immune Surveillance or Evasion , 2018, Front. Immunol..

[139]  A. Rademaker,et al.  A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer , 2018, Oncotarget.

[140]  M. Duffy,et al.  Mutant p53 in breast cancer: potential as a therapeutic target and biomarker , 2018, Breast Cancer Research and Treatment.

[141]  Hailin Zhao,et al.  The role of osteopontin in the progression of solid organ tumour , 2018, Cell Death & Disease.

[142]  M. Ilyas,et al.  Tumour-draining axillary lymph nodes in patients with large and locally advanced breast cancers undergoing neoadjuvant chemotherapy (NAC): the crucial contribution of immune cells (effector, regulatory) and cytokines (Th1, Th2) to immune-mediated tumour cell death induced by NAC , 2018, BMC Cancer.

[143]  Justin Lucas,et al.  A CD3-bispecific molecule targeting P-cadherin demonstrates T cell-mediated regression of established solid tumors in mice , 2018, Cancer Immunology, Immunotherapy.

[144]  Yuhua Wang,et al.  Combination Immunotherapy of MUC1 mRNA Nano-vaccine and CTLA-4 Blockade Effectively Inhibits Growth of Triple Negative Breast Cancer. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.

[145]  L. Dirix,et al.  Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study , 2017, Breast Cancer Research and Treatment.

[146]  Rongxiu Li,et al.  Combination Therapy with Bispecific Antibodies and PD-1 Blockade Enhances the Antitumor Potency of T Cells. , 2017, Cancer research.

[147]  Jianlin Shi,et al.  Tumor-selective catalytic nanomedicine by nanocatalyst delivery , 2017, Nature Communications.

[148]  R. Powers,et al.  Glucose Limitation Alters Glutamine Metabolism in MUC1-Overexpressing Pancreatic Cancer Cells , 2017, Journal of proteome research.

[149]  T. McGaha,et al.  Type I Interferon in Chronic Virus Infection and Cancer. , 2017, Trends in immunology.

[150]  J. Hassell,et al.  Ex vivo expanded natural killer cells from breast cancer patients and healthy donors are highly cytotoxic against breast cancer cell lines and patient-derived tumours , 2017, Breast Cancer Research.

[151]  Zuoheng Wang,et al.  Elevated T cell activation score is associated with improved survival of breast cancer , 2017, Breast Cancer Research and Treatment.

[152]  Hao Jiang,et al.  Ginsenoside Rg3 promotes cytotoxicity of Paclitaxel through inhibiting NF-κB signaling and regulating Bax/Bcl-2 expression on triple-negative breast cancer. , 2017, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[153]  J. Wolchok,et al.  Cancer immunotherapy — immune checkpoint blockade and associated endocrinopathies , 2017, Nature Reviews Endocrinology.

[154]  Lajos Pusztai,et al.  Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  Janice S. Sung,et al.  A Pilot Study of Preoperative Single-Dose Ipilimumab and/or Cryoablation in Women with Early-Stage Breast Cancer with Comprehensive Immune Profiling , 2016, Clinical Cancer Research.

[156]  E. Estrada-Muñiz,et al.  The anacardic 6-pentadecyl salicylic acid induces macrophage activation via the phosphorylation of ERK1/2, JNK, P38 kinases and NF-κB. , 2015, International immunopharmacology.

[157]  Y. Yoshioka,et al.  Generation and characterization of a bispecific diabody targeting both EPH receptor A10 and CD3. , 2015, Biochemical and biophysical research communications.

[158]  Carsten Denkert,et al.  Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences , 2014, Oncotarget.

[159]  Y. Yoshioka,et al.  Ephrin receptor A10 is a promising drug target potentially useful for breast cancers including triple negative breast cancers. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[160]  Y. Akagi,et al.  Feasibility study of personalized peptide vaccination for metastatic recurrent triple-negative breast cancer patients , 2014, Breast Cancer Research.

[161]  Y. Zeng,et al.  Clinical Activity of Adjuvant Cytokine-Induced Killer Cell Immunotherapy in Patients with Post-Mastectomy Triple-Negative Breast Cancer , 2014, Clinical Cancer Research.

[162]  Borivoj Vojnovic,et al.  Antagonism of EGFR and HER3 Enhances the Response to Inhibitors of the PI3K-Akt Pathway in Triple-Negative Breast Cancer , 2014, Science Signaling.

[163]  J. Abrams,et al.  Induction of proapoptotic antibodies to triple‐negative breast cancer by vaccination with TRAIL death receptor DR5 DNA , 2012, International journal of cancer.

[164]  V. Tuohy,et al.  An autoimmune-mediated strategy for prophylactic breast cancer vaccination , 2010, Nature Medicine.

[165]  L. Wakefield,et al.  Development of oncolytic adenovirus armed with a fusion of soluble transforming growth factor-beta receptor II and human immunoglobulin Fc for breast cancer therapy. , 2006, Human gene therapy.

[166]  W. Yokoyama,et al.  How do natural killer cells find self to achieve tolerance? , 2006, Immunity.

[167]  P. Kufer,et al.  BiTEs: bispecific antibody constructs with unique anti-tumor activity. , 2005, Drug discovery today.

[168]  Jie Zhang,et al.  [Effect of ginsenoside Rg3 on the progression of orthotopically xenotransplanted human breast cancer in nude mice and its mechanism]. , 2003, Sichuan da xue xue bao. Yi xue ban = Journal of Sichuan University. Medical science edition.

[169]  Kazuyoshi Takeda,et al.  New aspects of natural-killer-cell surveillance and therapy of cancer , 2002, Nature Reviews Cancer.

[170]  E. Alnemri,et al.  Natural Killer (NK) Cell–mediated Cytotoxicity: Differential Use of  TRAIL and Fas Ligand by Immature and Mature Primary Human NK Cells , 1998, The Journal of experimental medicine.

[171]  E. Elgabry,et al.  Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study , 2019, JAMA oncology.

[172]  K. Mangold,et al.  An Oncolytic Adenovirus Targeting Transforming Growth Factor b Inhibits Protumorigenic Signals and Produces Immune Activation: A Novel Approach to Enhance Anti-PD-1 and Anti-CTLA-4 Therapy , 2019 .

[173]  Guangyu Liu,et al.  Cisplatin and gemcitabine as the first line therapy in metastatic triple negative breast cancer , 2015, International journal of cancer.

[174]  V. Kataja,et al.  Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.